John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)
April 20, 2023 11:06 AM EDTUpdated 04:36 PM
R&D

BeiGene notch­es win for PD-1 drug in stom­ach can­cers. When will part­ner No­var­tis sub­mit for ap­proval?

Lei Lei Wu

News Reporter

BeiGene an­nounced Thurs­day morn­ing that its im­mune check­point in­hibitor helped pa­tients with cer­tain stom­ach can­cers live longer than chemother­a­py alone. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times